Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nouhi, Z.
Right arrow Articles by Ali, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nouhi, Z.
Right arrow Articles by Ali, S.
[Cancer Research 66, 1824-1832, February 1, 2006]
© 2006 American Association for Cancer Research


Endocrinology

Defining the Role of Prolactin as an Invasion Suppressor Hormone in Breast Cancer Cells

Zaynab Nouhi1,2, Naila Chughtai1,2, Strachan Hartley1,2, Eftihia Cocolakis1, Jean-Jacques Lebrun1 and Suhad Ali1,2

1 Hormones and Cancer Research Unit, and 2 The Division of Hematology, Department of Medicine, McGill University, Montreal, Quebec, Canada

Requests for reprints: Suhad Ali, Royal Victoria Hospital, H5-81, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1. Phone: 514-934-1934 ex. 34863; Fax: 514-982-0893; E-mail: suhad.ali{at}muhc.mcgill.ca.

Prolactin hormone (PRL) is well characterized as a terminal differentiation factor for mammary epithelial cells and as an autocrine growth/survival factor in breast cancer cells. However, this function of PRL may not fully signify its role in breast tumorigenesis. Cancer is a complex multistep progressive disease resulting not only from defects in cell growth but also in cell differentiation. Indeed, dedifferentiation of tumor cells is now recognized as a crucial event in invasion and metastasis. PRL plays a critical role in inducing/maintaining differentiation of mammary epithelial cells, suggesting that PRL signaling could serve to inhibit tumor progression. We show here that in breast cancer cells, PRL and Janus-activated kinase 2, a major kinase involved in PRL signaling, play a critical role in regulating epithelial-mesenchymal transformation (EMT), an essential process associated with tumor metastasis. Activation of the PRL receptor (PRLR), achieved by restoring PRL/JAK2 signaling in mesenchymal-like breast cancer cells, MDA-MB-231, suppressed their mesenchymal properties and reduced their invasive behavior. While blocking PRL autocrine function in epithelial-like breast cancer cells, T47D, using pharmacologic and genetic approaches induced mesenchymal-like phenotypic changes and enhanced their invasive propensity. Moreover, our results indicate that blocking PRL signaling led to activation of mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2) and transforming growth factor-ß/Smad signaling pathways, two major prometastatic pathways. Furthermore, our results indicate that following PRL/JAK2 inhibition, ERK1/2 activation precedes and is required for Smad2 activation and EMT induction in breast cancer cells. Together, these results highlight PRL as a critical regulator of epithelial plasticity and implicate PRL as an invasion suppressor hormone in breast cancer. (Cancer Res 2006; 66(3): 1824-32)




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Y. Hao, A. Chun, K. Cheung, B. Rashidi, and X. Yang
Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP
J. Biol. Chem., February 29, 2008; 283(9): 5496 - 5509.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee
What Can We Learn from Rodents about Prolactin in Humans?
Endocr. Rev., February 1, 2008; 29(1): 1 - 41.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Cocolakis, M. Dai, L. Drevet, J. Ho, E. Haines, S. Ali, and J.-J. Lebrun
Smad Signaling Antagonizes STAT5-mediated Gene Transcription and Mammary Epithelial Cell Differentiation
J. Biol. Chem., January 18, 2008; 283(3): 1293 - 1307.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. M. Neilson, J. Zhu, J. Xie, M. G. Malabarba, K. Sakamoto, K.-U. Wagner, R. A. Kirken, and H. Rui
Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways
Mol. Endocrinol., September 1, 2007; 21(9): 2218 - 2232.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
C. Manhes, C. Kayser, P. Bertheau, B. Kelder, J. J Kopchick, P. A Kelly, P. Touraine, and V. Goffin
Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma.
J. Endocrinol., August 1, 2006; 190(2): 271 - 285.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.